Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopsys places 180 Mammotome breast biopsy systems in U.S., company says.

This article was originally published in The Gray Sheet

Executive Summary

BIOPSYS MEDICAL PLACES 180 MAMMOTOME BREAST BIOPSY SYSTEMS IN U.S. since the August 1995 domestic roll-out of the product, Biopsys President and CEO Steven Gex told investors at a Piper Jaffray investment conference in Minneapolis on June 4. Over 6,000 breast cancer diagnoses have been performed with the Mammotome Biopsy System in U.S. physician's offices, hospitals, and breast imaging centers to date, Gex said. The system was formally introduced at the November 1995 Radiological Society of North America annual meeting ("The Gray Sheet" Dec. 4, 1995, p. 11).



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts